MedPath

JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMET L.L.C.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Safety Study of Mebendazole in Children 2 to 10 Years of Age

Phase 3
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2010-08-02
Last Posted Date
2014-03-12
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
397
Registration Number
NCT01173562

A Study of 28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Other: no intervention
Drug: Canagliflozin/Placebo Placebo/Canagliflozin
First Posted Date
2010-08-02
Last Posted Date
2012-01-02
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
26
Registration Number
NCT01173549

The Effect of Ketamine on Attentiveness

Phase 1
Completed
Conditions
Schizophrenia
Interventions
Drug: Placebo
First Posted Date
2010-07-19
Last Posted Date
2010-08-06
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
24
Registration Number
NCT01165294

A Drug Interaction Study of 31001074 and Paroxetine in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: 31001074/paroxetine
First Posted Date
2010-07-09
Last Posted Date
2014-04-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
14
Registration Number
NCT01159821

A Pharmacokinetic and Bioavailability Study of 28431754 (Canagliflozin) in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2010-07-05
Last Posted Date
2014-04-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
9
Registration Number
NCT01157000

A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia

First Posted Date
2010-06-25
Last Posted Date
2014-05-28
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
212
Registration Number
NCT01150448

A Pharmacokinetic and Drug Interaction Study of JNJ-26489112 in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Drug combination/ 26489112
First Posted Date
2010-06-22
Last Posted Date
2014-04-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
20
Registration Number
NCT01147887

A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus

Phase 1
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
First Posted Date
2010-05-24
Last Posted Date
2013-05-29
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
39
Registration Number
NCT01128985

A Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of an Intravenous Solution of JNJ-39588146 or Placebo in Patients With Heart Failure

Phase 2
Completed
Conditions
Heart Failure
Interventions
Drug: JNJ-39588146 5 ng/kg/min
Drug: JNJ-39588146 15 ng/kg/min
Drug: JNJ-39588146 5, 15, or 30 ng/kg/min
Drug: JNJ-39588146 30 ng/kg/min
Drug: Placebo
First Posted Date
2010-05-10
Last Posted Date
2013-07-19
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
62
Registration Number
NCT01120210

An Efficacy and Safety Study of Prucalopride in Participants With Chronic Constipation

Phase 3
Completed
Conditions
Constipation
Interventions
Drug: Placebo
First Posted Date
2010-05-04
Last Posted Date
2017-03-21
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
507
Registration Number
NCT01116206
© Copyright 2025. All Rights Reserved by MedPath